Literature DB >> 8480514

Experimental emetine myopathy: enzyme histochemical, electron microscopic, and immunomorphological studies.

N J Hopf1, H H Goebel.   

Abstract

Ipecac, containing emetine hydrochloride, is used by patients with anorexia nervosa to induce vomiting. Its chronic usage may result in a myopathy and a cardiomyopathy, the former marked by cytoplasmic bodies. We studied myopathological changes after daily injections of female Wistar rats with emetine hydrochloride intraperitoneally for periods of 4, 5, 9, and 10 weeks. The extensor digitorum longus muscle and the soleus muscle showed core-like lesions, streaming of the z-discs, nemaline bodies, cytoplasmic bodies, and spheroid cytoplasmic bodies. Immunomorphological studies revealed increased amounts of desmin. During a period of repair, i.e., 2, 4, and 6 weeks after termination of emetine application, these myopathological alterations faded while proliferation of the T-tubular system, i.e., honeycomb structures, was more often prevalent. Pathological features completely disappeared between 6 and 12 weeks of recovery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480514     DOI: 10.1007/bf00334453

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  22 in total

1.  Fatal myocarditis due to emetine hydrochloride.

Authors:  T H BREM; B E KONWALER
Journal:  Am Heart J       Date:  1955-09       Impact factor: 4.749

2.  Mitochondrial protein synthesis: inhibition by emetine hydrochloride.

Authors:  P S Lietman
Journal:  Mol Pharmacol       Date:  1971-03       Impact factor: 4.436

3.  Emetine myopathy.

Authors:  D D Duane; A G Engel
Journal:  Neurology       Date:  1970-08       Impact factor: 9.910

4.  Observations on the mechanism of emetine poisoning of myocardial tissue.

Authors:  B M Beller
Journal:  Circ Res       Date:  1968-04       Impact factor: 17.367

5.  Death from ipecac intoxication in a patient with anorexia nervosa.

Authors:  E J Friedman
Journal:  Am J Psychiatry       Date:  1984-05       Impact factor: 18.112

6.  Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders.

Authors:  E P Palmer; A T Guay
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

7.  Binge-eating and vomiting: a survey of a college population.

Authors:  K A Halmi; J R Falk; E Schwartz
Journal:  Psychol Med       Date:  1981-11       Impact factor: 7.723

8.  The distribution of intermediate filament protein (skeletin) in normal and diseased human skeletal muscle--an immunohistochemical and electron-microscopic study.

Authors:  L E Thornell; L Edström; A Eriksson; K G Henriksson; K A Angqvist
Journal:  J Neurol Sci       Date:  1980-08       Impact factor: 3.181

9.  Emetine myopathy in the rat.

Authors:  W G Bradley; J D Fewings; J B Harris; M A Johnson
Journal:  Br J Pharmacol       Date:  1976-05       Impact factor: 8.739

10.  Reversible ipecac myopathy.

Authors:  J E Mateer; B J Farrell; S S Chou; L Gutmann
Journal:  Arch Neurol       Date:  1985-02
View more
  4 in total

Review 1.  Heart failure in anorexia nervosa: case report and review of the literature.

Authors:  C L Birmingham; S Gritzner
Journal:  Eat Weight Disord       Date:  2007-03       Impact factor: 4.652

Review 2.  [Congenital and other myopathies].

Authors:  H H Goebel; H D Müller; R Schröder
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

3.  A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors.

Authors:  Peng-Xuan Ren; Wei-Juan Shang; Wan-Chao Yin; Huan Ge; Lin Wang; Xiang-Lei Zhang; Bing-Qian Li; Hong-Lin Li; Ye-Chun Xu; Eric H Xu; Hua-Liang Jiang; Li-Li Zhu; Lei-Ke Zhang; Fang Bai
Journal:  Acta Pharmacol Sin       Date:  2021-04-27       Impact factor: 7.169

4.  Emetine Synergizes with Cisplatin to Enhance Anti-Cancer Efficacy against Lung Cancer Cells.

Authors:  Ti-Hui Wu; Shan-Yueh Chang; Yu-Lueng Shih; Tsai-Wang Huang; Hung Chang; Ya-Wen Lin
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.